Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

New research reveals how sleep apnea may accelerate brain aging and cognitive decline, with experts sharing crucial insights ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

Sleep apnea is known to wreak havoc with the body, contributing to heart problems, diabetes and liver disease. The sleep disorder also appears to have direct effects on brain health, a new study ...

Share on Pinterest A new study links sleep apnea to changes in key brain regions related to memory. Image credit: Maskot/Getty Images. About 936 million adults around the world have sleep apnea.

There are many breakthroughs in medicine regarding the treatment of obstructive sleep apnea, and a weight loss drug might ...